SCHEMBL20600976

SCHEMBL20600976

O=C(NC(c1ccccc1)C1CCN(C(=O)O)CC1)c1ccc(Cl)s1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.42
F10 P00742 5/20 0.42
MAPT P10636 1/20 0.42
RIPK1 Q13546 1/20 0.41
MAPK1 P28482 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
SMYD3 Q9H7B4 3/20 0.40
TACR3 P29371 2/20 0.40
SLC6A9 P48067 1/20 0.40
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
MEN1 O00255 1/20 0.39
KCNK3 O14649 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20600974 1.00 SMN1; SMN2 (0.42) SMN1; SMN2F10MAPTRIPK1MAPK1
SCHEMBL22023816 0.86 GPR119 (0.46) MAPTMAPK1KMT2AALDH1A1MEN1
SCHEMBL28351339 0.86 GPR119 (0.46) MAPTMAPK1KMT2AALDH1A1MEN1
SCHEMBL20601154 0.84 SMYD3 (0.56) SMN1; SMN2SMYD3TACR3HDAC3HDAC4
SCHEMBL20601151 0.84 SMYD3 (0.56) SMN1; SMN2SMYD3TACR3HDAC3HDAC4
SCHEMBL20600943 0.83 SMN1; SMN2 (0.46) SMN1; SMN2F10MAPTMAPK1KMT2A
SCHEMBL20600908 0.83 SMN1; SMN2 (0.46) SMN1; SMN2F10MAPTMAPK1KMT2A
SCHEMBL20600907 0.83 SMN1; SMN2 (0.46) SMN1; SMN2F10MAPTMAPK1KMT2A
SCHEMBL20601020 0.82 SMN1; SMN2 (0.56) SMN1; SMN2F10MAPK1KMT2ALMNA
SCHEMBL20600988 0.82 SMN1; SMN2 (0.56) SMN1; SMN2F10MAPK1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10927078-B2 Modulators of indoleamine 2,3-dioxygenase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-02-23 US disclosed
US-20200165201-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-05-28 US disclosed
EP-3645520-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-05-06 EP disclosed
CN-110709391-A Modulators of indoleamine2, 3-dioxygenase 葛兰素史克知识产权开发有限公司 2020-01-17 CN disclosed
WO-2019003141-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200165201-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, TPH1 SMN1; SMN2 2957/4885F10 4553/4885MAPT 1969/4885
US-10927078-B2 Modulators of indoleamine 2,3-dioxygenase IDO1, IDO2, TPH1 SMN1; SMN2 2957/4885F10 4553/4885MAPT 1969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.